Related Experiment Video
Updated: May 12, 2026
Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Clinicopathological significance of 5'-3' exoribonuclease 2 expression in small cell lung cancer tissues
Rui Lin1, Feng Chen2, Wei Zhang1
1Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, People's Republic of China.
Abstract:
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy. Overall survival in SCLC patients remains poor, and there is a lack of treatment options after the failure of first-line therapy. 5'-3' exoribonuclease 2 (XRN2) is associated with tumor progression. However, its mechanism in SCLC remains unclear. In this study, we collected and analyzed the expression data for XRN2 mRNA in SCLC and non-cancer lung tissues, as well as pan-cancer and non-cancer tissues from high-throughput datasets and identified XRN2 expression was significantly correlated with the prognosis of SCLC patients. Gene Ontology analysis indicated that XRN2 may promote tumor cell growth and development through biological processes. XRN2 performed better at distinguishing between the control group and samples of many tumors. Based on the TIMER and ESTIMATE algorithm analyses, this study revealed that XRN2 may act as a stimulator of immune responses in many tumors.Together,XRN2 overexpression may be associated with SCLC cell proliferation, migration, and invasion. High XRN2 expression is related to poor prognosis in SCLC and several other cancer types. XRN2 may also stimulate immune responses in many tumors.
Insights
High expression of 5'-3' exoribonuclease 2 (XRN2) is linked to poor prognosis in small cell lung cancer (SCLC). XRN2 may drive SCLC progression and stimulate immune responses in various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with poor survival rates.
- Limited treatment options exist for SCLC patients post-first-line therapy failure.
- The role of 5'-3' exoribonuclease 2 (XRN2) in SCLC pathogenesis is not well understood.
Purpose of the Study:
- To investigate the expression and prognostic significance of XRN2 in SCLC.
- To explore the potential mechanisms underlying XRN2's role in SCLC progression.
- To assess XRN2's association with immune responses across various cancer types.
Main Methods:
- Analysis of XRN2 mRNA expression data in SCLC and non-cancerous lung tissues.
- Utilized high-throughput datasets for pan-cancer and non-cancer tissue analysis.
- Employed Gene Ontology analysis, TIMER, and ESTIMATE algorithms.
Main Results:
- XRN2 expression significantly correlates with SCLC patient prognosis.
- Gene Ontology analysis suggests XRN2 promotes tumor cell growth and development.
- XRN2 expression is associated with immune cell infiltration and may stimulate immune responses in tumors.
- High XRN2 expression correlates with poor prognosis in SCLC and other cancers.
Conclusions:
- XRN2 overexpression is linked to SCLC cell proliferation, migration, and invasion.
- Elevated XRN2 expression indicates a poor prognosis for SCLC patients.
- XRN2 may serve as a potential therapeutic target and prognostic biomarker in SCLC and other malignancies.
